Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)

NCT04170556 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Regorafenib
DRUG: Nivolumab

Sponsor

Fundacion Clinic per a la Recerca Biomédica

Collaborators

[object Object]